Insulin resistance, adipokine profile and hepatic expression of SOCS-3 gene in chronic hepatitis C

Table 4 Adipokines and liver inflammation in chronic hepatitis C

	G≥2 (n= 9)		G < 2 (n= 22)		Pvalue
	Median (LQ-UQ)	Min-max	Median (LQ-UQ)	Min-max
Omentin (ng/mL)	381.24 (367.16-522.77)	115.7-757.34	389.46 (340.33-483.33)	227.99-735.84	P > 0.05
Adiponectin (μg/mL)	6.21 (5.71-7.56)	4.6-9.07	8 (5.48-9.06)	3.51-18.24	P > 0.05
Resistin (ng/mL)	1.24 (1.17-1.65)	0.91-2.36	1.55 (1.11-1.82)	0.73-2.92	P > 0.05
HOMA	2.1(1.59-3.99)	0.78-9.67	2.38 (1.25-2.84)	0.88-7.25	P > 0.05
Leptin (ng/mL)	10.83 (4.26-31.44)	1.69-54.65	3.43 (1.83-9.36)	0.77-39.04	P > 0.05
Visfatin (ng/mL)	2.05 (1.83-2.66)	0.65-8.89	2.78 (1.17-4.08)	0.45-9.37	P > 0.05
Osteopontin (ng/mL)	34.04 (32.7-36.19)	22.47-49.12	23.25 (15.05-36.07)	5.33-59.15	P = 0.03
SOCS-3	3.69 (2.67-7.05)	0.66-11.52	8.13 (1.74-11.78)	0.5-24.53	P > 0.05

Inflammatory activity (G ≥ 2) was associated with increased osteopontin concentration (34.04 vs 23.35, P = 0.03). No relationships were found between other adipokine concentrations and the grade of inflammatory activity. n: Number of patients, in liver biopsy: G: Grade of inflammation and necrosis; HOMA-IR: Homeostasis model assessment of insulin resistance; LQ: Lower quartile; UQ: Upper quartile.